Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LCH004
MIFTS: 41

Lichen Disease

Categories: Skin diseases
Genes Tissues Related diseases Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lichen Disease

About this section

MalaCards integrated aliases for Lichen Disease:

Name: Lichen Disease 12 15 73

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:8574
ICD10 33 L28.0 L43.9
ICD9CM 35 697 697.9
UMLS 73 C0023643
Sources

Summaries for Lichen Disease

About this section
MalaCards based summary : Lichen Disease is related to lichen planus and selective igg deficiency disease, and has symptoms including pruritus and related conditions An important gene associated with Lichen Disease is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Triamcinolone and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin and bone, and related phenotypes are cellular and homeostasis/metabolism

Sources

Related Diseases for Lichen Disease

About this section

Diseases related to Lichen Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 lichen planus 26.5 COL17A1 CXCR3 DST ICAM1 IFNG IL4
2 selective igg deficiency disease 10.8 CD40LG CD79A
3 c1q nephropathy 10.8 CD40LG CD79A
4 neuroschistosomiasis 10.8 CD79A IFNG
5 lichen planus pemphigoides 10.8 COL17A1 DST
6 meningovascular neurosyphilis 10.8 CD40LG CD79A
7 alpha chain disease 10.8 CD40LG CD79A
8 brill-zinsser disease 10.8 CD40LG CD79A
9 exudative glomerulonephritis 10.8 CD40LG CD79A
10 cork-handlers' disease 10.8 CD40LG CD79A
11 pemphigoid gestationis 10.8 COL17A1 DST
12 salpingo-oophoritis 10.8 CD40LG CD79A
13 staphylococcal toxic shock syndrome 10.8 IFNG TNF
14 early yaws 10.8 CD40LG CD79A
15 autoimmune myocarditis 10.8 IFNG TNF
16 ventilation pneumonitis 10.8 CD40LG CD79A
17 chronic interstitial cystitis 10.8 CD40LG CD79A
18 axillary adenitis 10.8 CD40LG CD79A
19 cryofibrinogenemia 10.8 CD40LG CD79A
20 trichostrongyloidiasis 10.8 CD40LG CD79A
21 subacute bacterial endocarditis 10.8 CD40LG CD79A
22 immunoglobulin g deficiency 10.7 CD40LG CD79A
23 orbital granuloma 10.7 CD40LG CD79A
24 transient hypogammaglobulinemia of infancy 10.7 CD40LG CD79A
25 hyperglobulinemic purpura 10.7 CD40LG CD79A
26 gastroduodenitis 10.7 CD40LG CD79A
27 bacterial conjunctivitis 10.7 CD40LG CD79A
28 heavy chain disease 10.7 CD40LG CD79A
29 neurotic excoriation 10.7 COL17A1 DST
30 tropical endomyocardial fibrosis 10.7 IL4 TNF
31 ophthalmia neonatorum 10.7 CD40LG CD79A
32 trench fever 10.7 CD40LG TNF
33 parotid disease 10.7 CD40LG CD79A
34 mycoplasmal pneumonia 10.7 IFNG IL4
35 rheumatoid lung disease 10.7 CD40LG TNF
36 herpetiform pemphigus 10.7 DSG1 DST
37 cerebral arteritis 10.7 CD40LG CD79A
38 selective immunoglobulin deficiency disease 10.6 CD40LG CD79A
39 linear iga disease 10.6 CD79A COL17A1 DST
40 invasive aspergillosis 10.6 CD79A IFNG TLR9
41 central nervous system vasculitis 10.6 CD40LG TLR9 TNF
42 clonorchiasis 10.6 CD79A IFNG TNF
43 ocular toxoplasmosis 10.6 CD40LG CD79A TLR9
44 filariasis 10.6 IFNG TLR9 TNF
45 trichosporonosis 10.6 IFNG TNF
46 vesiculobullous skin disease 10.6 CD79A COL17A1 DST
47 epidermolysis bullosa acquisita 10.6 CD79A COL17A1 DST
48 autoimmune disease of urogenital tract 10.6 CD40LG CD79A TLR9
49 cicatricial pemphigoid 10.6 CD79A COL17A1 DST
50 miller fisher syndrome 10.6 CD40LG TNF

Graphical network of the top 20 diseases related to Lichen Disease:



Diseases related to Lichen Disease
Sources

Symptoms & Phenotypes for Lichen Disease

About this section

UMLS symptoms related to Lichen Disease:


pruritus and related conditions

MGI Mouse Phenotypes related to Lichen Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 IL4 FOXP3 CD40LG ICAM1 CD79A IFNG
2 homeostasis/metabolism MP:0005376 10.18 IL4 FOXP3 CD40LG ICAM1 CD79A IFNG
3 hematopoietic system MP:0005397 10.13 CXCR3 IL4 FOXP3 CD40LG ICAM1 CD79A
4 immune system MP:0005387 10.07 IFNG CXCR3 IL4 FOXP3 CD40LG ICAM1
5 digestive/alimentary MP:0005381 10 IFNG FOXP3 ICAM1 TNF IL4 TP53
6 mortality/aging MP:0010768 10 CXCR3 IFNG FOXP3 CD40LG ICAM1 TNF
7 integument MP:0010771 9.92 DSG1 IL4 FOXP3 CD40LG ICAM1 IFNG
8 neoplasm MP:0002006 9.63 CXCR3 IFNG ICAM1 CD79A TNF TP53
9 renal/urinary system MP:0005367 9.56 IL4 FOXP3 CD40LG CD79A IFNG CXCR3
10 vision/eye MP:0005391 9.17 IFNG DSG1 FOXP3 ICAM1 TNF IL4
Sources

Drugs & Therapeutics for Lichen Disease

About this section

Drugs for Lichen Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 124-94-7 31307
2
Tacrolimus Approved, Investigational Phase 4,Phase 2,Not Applicable 104987-11-3 445643 439492
3
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 378-44-9 9782
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
5
Pimecrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 137071-32-0 6447131 17753757
6
Apremilast Approved, Investigational Phase 4,Phase 2 608141-41-9 11561674
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 22916-47-8 4189
8
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
10
Zinc Approved, Investigational Phase 4 7440-66-6 23994
11
Insulin glulisine Approved Phase 4 207748-29-6
12 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
13
Chitosan Approved, Nutraceutical Phase 4 9012-76-4 71853
14
Glucosamine Approved, Investigational, Nutraceutical Phase 4 3416-24-8 439213
15 Lycopene Approved, Investigational, Nutraceutical Phase 4,Phase 2 502-65-8 446925
16
Lactitol Investigational Phase 4 585-86-4 3871
17 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
18 Betamethasone Valerate Phase 4,Phase 3,Phase 2,Not Applicable 2152-44-5
19 Analgesics Phase 4,Phase 3,Phase 2,Early Phase 1
20 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
21 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Early Phase 1
23 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
25 Dermatologic Agents Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
26 Angiogenesis Inhibitors Phase 4,Phase 2
27 Triamcinolone diacetate Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
28 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
29 Hormones Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 2
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
32 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
37 Antiemetics Phase 4,Phase 3,Phase 2,Early Phase 1
38 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
39 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2
43 Autonomic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
44 Betamethasone benzoate Phase 4,Phase 3,Phase 2,Not Applicable
45 Betamethasone sodium phosphate Phase 4,Phase 3,Phase 2,Not Applicable
46 Betamethasone-17,21-dipropionate Phase 4,Phase 3,Phase 2,Not Applicable
47 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
48 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Early Phase 1
49 Prednisolone acetate Phase 4,Phase 2
50 insulin Phase 4

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Management of Pain in Oral Lichen Planus Completed NCT03572959 Phase 4 0.1 % topical triamcinolone acetonide
2 Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus Completed NCT02858297 Phase 4 Glucosamine sulfate;triamcinolone acetonide
3 A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus Completed NCT02587117 Phase 4 lycopene;Prednisolone
4 Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus Completed NCT02443311 Phase 4 Pimecrolimus 1% cream;Betamethasone 17-valerate 0.1% cream
5 Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Enrolling by invitation NCT02914886 Phase 4 Apidra;current insulin
6 Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Not yet recruiting NCT03422640 Phase 4 Apremilast
7 The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus Unknown status NCT01083420 Phase 3 Minocycline;Dexamethasone
8 Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT Unknown status NCT01282515 Phase 2, Phase 3 clobetasolpropionate;hexaminolevulinate
9 Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus Completed NCT02329600 Phase 3 green tea tablets (Green tea extract 5:1) 200 mg;Triamcinolone Acetonide
10 Efficacy of Elidel Cream on Erosive Oral Lichen Planus Completed NCT00130572 Phase 3 Pimecrolimus
11 Chamaemelum Nobile 2% Versus Placebo Topic Gel to Treat Oral Lichen Planus Completed NCT02421770 Phase 3
12 Photodynamic Therapy for Oral Precursor Lesions Completed NCT01497951 Phase 3
13 Clobetasol Proprionate Versus Fractionated CO2 Laser for the Treatment of Lichen Sclerosus Recruiting NCT02573883 Phase 3 Clobetasol Propionate 0.05% ointment
14 Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral Lichen Terminated NCT01061853 Phase 3 TOPICAL SIROLIMUS (RAPAMUNE*);TOPICAL BETAMETHASONE 0.05%
15 A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus Unknown status NCT01524744 Phase 2 Pimecrolimus ointment;Adcortyl
16 Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus Unknown status NCT01041625 Phase 2 Apremilast (CC-10004)
17 Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin Unknown status NCT01538732 Phase 2 alitretinoin
18 Treatmant of Oral Lichen Planus With Lycopene Completed NCT00656214 Phase 2 Lycopene;Placebo
19 Pimecrolimus Cream for Oral Lichen Planus Completed NCT00297037 Phase 2 Pimecrolimus 1% cream
20 Efficacy of Purslane in Treatment of Oral Lichen Planus Completed NCT00746772 Phase 2 Purslane 235mg/day in one dosage;Placebo : one dosage
21 A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus Completed NCT00525421 Phase 2 Curcuminoids;Placebo
22 Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on Lichen Planus Completed NCT02453503 Phase 2 Licorice;Triamcinolone Acetonide
23 The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus Completed NCT02106468 Phase 2 Prednisone tablet 5mg;Omega-3 soft capsules 1000 mg
24 Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus Completed NCT00757874 Phase 2 Tacrolimus cream;Clobetasol cream
25 Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus Completed NCT02744378 Phase 2 Tacrolimus 0.1%;Clobetasol 0.05%
26 Cedar Honey in Oral Lichen Planus Completed NCT01974414 Phase 1, Phase 2 orally administered cedar honey
27 Dexamethasone to Treat Oral Lichen Planus Completed NCT00111072 Phase 2 dexamethasone 0.01% solution
28 Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus Completed NCT00102557 Phase 2 Hydroxychloroquine
29 Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus Completed NCT00393263 Phase 2 pimecrolimus and clobetasol;clobetasol 0.05% cream
30 Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other Completed NCT00484250 Phase 2 metronidazole,doxycycline
31 Topical "Non-Aromatic Very Rich in Steranes" (NAVS) Naphthalan for the Treatment of Oral Mucosal Diseases Completed NCT02920658 Phase 2 NAVS Naphthalan;0.05% Betamethasone dipropionate
32 Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Completed NCT00507832 Phase 2 Pimecrolimus;Hydrocortisone;Pimecrolimus
33 A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) Completed NCT02196324 Phase 2 serlopitant;Placebo
34 Valchlor in the Treatment of Lichen Planopilaris Recruiting NCT03417141 Phase 2 Valchlor
35 Dexamethasone Solution for the Treatment of Oral Lichen Planus Recruiting NCT02850601 Phase 2 Dexamethasone
36 Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus Recruiting NCT03026478 Phase 2 Betamethasone Dipropionate;Clobetasol Propionate
37 Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus Recruiting NCT03386643 Phase 2 Bifidobacterium animalis subsp. lactis HN019;Clobetasol propionate 0.05%
38 Efficacy of Intralesional Injection of Platelet Rich Plasma in the Treatment of Patients With Erosive Oral Lichen Planus Not yet recruiting NCT03293368 Phase 2 Triamcinolone Acetonide
39 Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions. Not yet recruiting NCT03509675 Phase 2 Non-Steroidal Anti-inflammatory Topical Rinse;Placebos
40 Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus Terminated NCT01126255 Phase 2 Clobetasol propionate 0.05%;Progesterone 8%
41 A Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Curcuminoids in Oral Lichen Planus Terminated NCT00226174 Phase 2 Curcuminoids
42 Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream Terminated NCT00321750 Phase 2 1% pimecrolimus cream
43 A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus Terminated NCT00135733 Phase 2 Amevive (Alefacept);Placebo
44 Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus Terminated NCT00285779 Phase 2 Etanercept;Placebo
45 Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Chronic Oral Pain Terminated NCT01584947 Phase 2 Bupivacaine;Placebo
46 Free Soft Tissue Graft in Treatment of Oral Lichen Planus Unknown status NCT00737854 Phase 1
47 Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus Unknown status NCT01375101 Phase 1 placebo;Quercetin
48 Methylene Blue Injection for Nonneoplastic Epithelial Disorders of Vulva Active, not recruiting NCT03200808 Phase 1 mixed methylene blue compound injection
49 Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus Unknown status NCT02532166 Not Applicable
50 Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus Unknown status NCT02276573 Not Applicable

Search NIH Clinical Center for Lichen Disease

Sources

Genetic Tests for Lichen Disease

About this section
Sources

Anatomical Context for Lichen Disease

About this section

MalaCards organs/tissues related to Lichen Disease:

41
Skin, Bone
Sources

Publications for Lichen Disease

About this section
Sources

Variations for Lichen Disease

About this section
Sources

Expression for Lichen Disease

About this section
Search GEO for disease gene expression data for Lichen Disease.
Sources

Pathways for Lichen Disease

About this section

Pathways related to Lichen Disease according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.94 CD40LG CD79A DSG1 ICAM1 IFNG IL4
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.27 CD40LG ICAM1 IFNG IL4 MX1 TNF
3
Allograft rejection 1 37
Show member pathways
 12.78 CD40LG FOXP3 ICAM1 IFNG IL4 TNF
4
IL-2 Pathway 64
Show member pathways
 12.71 CD79A IFNG IL4 TLR9 TNF
5
Regulation of IFNA signaling 66
Show member pathways
 12.56 IFNG IL4 MX1 TNF
6
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.43 ICAM1 IFNG IL4 TNF
7
Th17 cell differentiation 37
Show member pathways
 12.36 FOXP3 IFNG IL4 TNF
8
T cell receptor signaling pathway 37
Show member pathways
 12.34 CD40LG IFNG IL4 TNF
9
Influenza A 37
Show member pathways
 12.25 ICAM1 IFNG IL4 MX1 PABPN1 TLR9
10
NF-kappaB Signaling 4
12.21 CD40LG CD79A FOXP3 IFNG IL4 TLR9
11
Folate Metabolism 1
Show member pathways
 12.19 ICAM1 IFNG IL4 TNF TP53
12
Toxoplasmosis 37
Show member pathways
 12.18 CD40LG IFNG IL4 TNF
13
Bacterial infections in CF airways 22
Show member pathways
 12.1 IFNG IL4 TLR9 TNF
14
Colorectal Cancer Metastasis 64
12.09 IFNG TLR9 TNF TP53
15
Fluid shear stress and atherosclerosis 37
12 ICAM1 IFNG TNF TP53
16
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.88 CD79A IFNG IL4 TNF
17
Interleukin-4 and 13 signaling 66
11.85 ICAM1 IL4 TNF TP53
18
Spinal Cord Injury 1
11.85 ICAM1 IFNG IL4 TNF TP53
19
NF-kappa B signaling pathway 37
11.8 CD40LG ICAM1 TNF
20
Rheumatoid arthritis 37
11.77 ICAM1 IFNG TNF
21
Glucocorticoid receptor regulatory network 1
11.69 ICAM1 IFNG IL4 TP53
22
Dendritic Cells Developmental Lineage Pathway 65
11.67 IFNG TLR9 TNF
23
Innate Lymphoid Cell Differentiation Pathways 65
11.64 CXCR3 IFNG IL4 TNF
24
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.54 CD40LG FOXP3 IFNG IL4 TNF
25
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.5 CD40LG ICAM1 IFNG TNF
26
Photodynamic therapy-induced AP-1 survival signaling. 1
11.49 IFNG TNF TP53
27
Interleukin-10 signaling 66
11.46 ICAM1 IL4 TNF
28
Th2 Differentiation Pathway 65
11.43 FOXP3 IFNG IL4
29
Inflammatory Response Pathway 1
11.24 CD40LG IFNG IL4
30
Development and heterogeneity of the ILC family 1
11.22 IFNG IL4 TNF
31
Cytokines and Inflammatory Response 1
11.18 IFNG IL4 TNF
32
African trypanosomiasis 37
11.17 ICAM1 IFNG TLR9 TNF
33
LDL Oxidation in Atherogenesis 64
10.87 ICAM1 TNF
34
Malaria 37
10.71 CD40LG ICAM1 IFNG TLR9 TNF
Sources

GO Terms for Lichen Disease

About this section

Cellular components related to Lichen Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 CD40LG CD79A CXCR3 ICAM1 TNF
2 hemidesmosome GO:0030056 8.96 COL17A1 DST

Biological processes related to Lichen Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.95 CXCR3 DSG1 DST ICAM1 LPP
2 negative regulation of transcription, DNA-templated GO:0045892 9.92 FOXP3 IFNG IL4 TNF TP53
3 cytokine-mediated signaling pathway GO:0019221 9.86 ICAM1 IL4 TNF TP53
4 positive regulation of gene expression GO:0010628 9.83 FOXP3 IFNG TLR9 TNF TP53
5 regulation of immune response GO:0050776 9.8 CD40LG COL17A1 ICAM1 IL4
6 B cell differentiation GO:0030183 9.69 CD40LG CD79A IL4
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.67 CD40LG ICAM1 TLR9 TNF
8 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 IFNG TNF
9 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 ICAM1 IFNG TNF
10 regulation of regulatory T cell differentiation GO:0045589 9.57 FOXP3 IFNG
11 negative regulation of interleukin-17 production GO:0032700 9.54 FOXP3 IFNG
12 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.48 ICAM1 TNF
13 regulation of immunoglobulin secretion GO:0051023 9.46 CD40LG TNF
14 negative regulation of interleukin-6 production GO:0032715 9.33 FOXP3 TLR9 TNF
15 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IFNG TNF
16 positive regulation of vitamin D biosynthetic process GO:0060557 9.26 IFNG TNF
17 response to virus GO:0009615 9.26 FOXP3 IFNG MX1 TNF
18 positive regulation of interleukin-12 production GO:0032735 8.8 CD40LG IFNG TLR9

Molecular functions related to Lichen Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.83 CD40LG CD79A COL17A1 DSG1 DST FOXP3
2 cytokine activity GO:0005125 8.92 CD40LG IFNG IL4 TNF
Sources

Sources for Lichen Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....